Actavis buying Warner Chilcott in $8.5B deal
Actavis is buying Warner Chilcott in an all-stock deal valued at about $8.5 billion that would create the third-biggest specialty pharmaceutical company in the U.S. market.
Actavis is buying Warner Chilcott in an all-stock deal valued at about $8.5 billion that would create the third-biggest specialty pharmaceutical company in the U.S. market.
Shaken, not stirred, is the essence of new research that's showing promise in creating the chemical reactions necessary for industries such as pharmaceutical companies, but eliminating the resulting waste from traditional ...
(AP)—Clinical testing company Quintiles Transnational wants to become a public company again after nearly a decade in private hands.
A new stem cell-derived system for screening experimental drugs for cardiotoxicity could identify dangerous side effects early in the development process, thereby potentially saving time, lives and money, according to Evan ...
(Phys.org)—A joint research effort by the Friedrich-Loeffler-Institute and pharmaceutical company CureVac, both based in Germany, has resulted in the creation of a new type of flu vaccine. The vaccine, as the team describes ...
Two Michigan State University researchers have invented a protein purifier that could help pharmaceutical companies save time and money.
(AP) -- Shares of Millennial Media nearly doubled in the mobile advertising company's market debut Thursday.
Based on a recent study, University of Missouri and Oregon researchers believe a legal definition for what constitutes "cruelty-free" labeled products should be determined and manufacturers should be required to abide by ...
Consumers hold churches and pharmaceutical companies to different moral standards than other organizations, according to a new study in the Journal of Consumer Research.
(AP) -- Apple Inc. has named Arthur Levinson as its non-executive chairman, a move that rewards the longtime Apple board member who chose it over Google Inc. when the technology giants began to compete with ...
A breakthrough in the fight against drug-resistant infections is one step closer following the discovery of the structure of NDM-1: a vicious form of bacteria that is currently resistant to the most powerful antibiotics available.